Medicine and Dentistry
Antibiotic Resistance
100%
Antibiotics
73%
Disease
41%
Antiinfective Agent
38%
Infection
37%
Health Care Cost
33%
Low and Middle Income Countries
31%
COVID-19
24%
Public Health
22%
Health Care
14%
One Health
13%
Antimalarial Agent
10%
Household
10%
Health System
9%
Carbapenem-Resistant Enterobacteriaceae
8%
Antibiotics
8%
Prevalence
7%
Short Course Therapy
7%
Community Acquired Infection
7%
Hospital Infection
6%
Health Care Facility
6%
Malaria
6%
Malaria Control
6%
Pathogen
6%
Rotavirus Vaccine
5%
Infection Control
5%
Severe Acute Respiratory Syndrome Coronavirus 2
5%
Enterobacteriaceae Infection
5%
Mortality Rate
5%
Colistimethate
5%
Disability Adjusted Life Years
5%
Vaccination Coverage
5%
Drug Resistance
5%
Pharmacology, Toxicology and Pharmaceutical Science
Antibiotics
76%
Antibiotic Agent
68%
Infection
49%
Antimicrobial Resistance
49%
Antibiotic Resistance
37%
Disease
31%
Antiinfective Agent
31%
Drug Resistance
21%
Elimination
16%
Pandemic
15%
Antimalarial Agent
13%
Methicillin-Resistant Staphylococcus Aureus
13%
Observational Study
13%
Infectious Agent
11%
Vaccination Policy
11%
Prevalence
10%
Carbapenem
9%
Sepsis
8%
Acinetobacter
7%
Quinolone Derivative
6%
Drug Resistant Tuberculosis
6%
Antibiotic-Resistant Bacteria
5%
Multi-Drug-Resistant Tuberculosis
5%
Tuberculosis
5%
Keyphrases
Antimicrobial Resistance
70%
Antibiotic Use
49%
Antibiotic Resistance
34%
Antibiotics
30%
India
27%
Aid Reduction
17%
United States
17%
Infectious Diseases
14%
Antibiotic Stewardship
14%
Communication Tools
13%
Drug Resistance
13%
Low-middle Income Countries
12%
Antimicrobial Use
10%
Antibiotic Effectiveness
9%
South Asia
8%
Biological Resistance
8%
Healthcare-associated Infections
8%
One Health
8%
Determinants of Participation
8%
Antimicrobial Resistance Surveillance
8%
Vaccine Value
8%
Global Threats
8%
Microbes
8%
COVID-19 Pandemic
8%
Disease Burden
6%
Disease Threat
6%
Food-producing Animals
6%
High-level Meeting
6%
Vaccination
5%
Developing World
5%
Affordable Medicines
5%
Economic Burden
5%
Vulnerability
5%
Health Systems
5%
COVID-19
5%
Economic Incentives
5%
Baumannii
5%
Antimicrobial Stewardship
5%
Hospital Infection Control
5%
Antibiotic Development
5%
Uncertainty Interval
5%
Consumption Data
5%
